The Journal of Urology
Volume 182, Issue 1 , Pages 139-144, July 2009

Length of Positive Surgical Margin After Radical Prostatectomy as a Predictor of Biochemical Recurrence

  • Sergey Shikanov

      Affiliations

    • Nothing to disclose.
  • ,
  • Jie Song

      Affiliations

    • Nothing to disclose.
  • ,
  • Cassandra Royce

      Affiliations

    • Nothing to disclose.
  • ,
  • Hikmat Al-Ahmadie

      Affiliations

    • Nothing to disclose.
  • ,
  • Kevin Zorn

      Affiliations

    • Financial interest and/or other relationship with Intuitive Surgical and SurgRx, Inc.
  • ,
  • Gary Steinberg

      Affiliations

    • Financial interest and/or other relationship with Vysis, Bioniche and Spectrum.
  • ,
  • Gregory Zagaja

      Affiliations

    • Financial interest and/or other relationship with Intuitive Surgical.
  • ,
  • Arieh Shalhav

      Affiliations

    • Nothing to disclose.
  • ,
  • Scott Eggener

      Affiliations

    • Nothing to disclose.
    • Corresponding Author InformationCorrespondence: 5841 S. Maryland Ave., MC 6038, Chicago, Illinois 60637 (telephone: 773-702-5195; FAX: 773-702-1001)

University of Chicago, Chicago, Illinois

Received 15 December 2008 published online 18 May 2009.

Purpose

Length and location of positive surgical margins are independent predictors of biochemical recurrence after open radical prostatectomy. We assessed their impact on biochemical recurrence in a large robotic prostatectomy series.

Materials and Methods

Data were collected prospectively from 1,398 men undergoing robotic radical prostatectomy for clinically localized prostate cancer from 2003 to 2008 at a single institution. The associations of preoperative prostate specific antigen, pathological Gleason score, pathological stage and positive surgical margin parameters (location, length and focality) with biochemical recurrence rate were evaluated. Margin status and length were measured by a single uropathologist. Biochemical recurrence was defined as serum prostate specific antigen greater than 0.1 ng/ml on 2 consecutive tests. Cox regression models were constructed to evaluate predictors of biochemical recurrence.

Results

Of 1,398 consecutive patients who underwent robotic prostatectomy positive margins were present in 243 (17%) (11% of pathological T2 and 41% of T3). Preoperative prostate specific antigen, pathological stage, Gleason score, margin status, and margin length as a continuous and categorical variable (less than 1, 1 to 3, more than 3 mm) were independent predictors of biochemical recurrence. Patients with negative margins and those with a positive margin less than 1 mm had similar rates of biochemical recurrence (log rank test p = 0.18). Surgical margin location was not independently associated with biochemical recurrence.

Conclusions

Margin status and length are independent predictors of biochemical recurrence following robotic radical prostatectomy. Although longer followup and validation studies are necessary for confirmation, patients with a positive margin less than 1 mm appear to have similar recurrence rates as those with negative margins.

Key Words: prostatectomy, recurrence

Abbreviations and Acronyms: BCR, biochemical recurrence, BMI, body mass index, ECE, extracapsular extension, GS, Gleason score, PSA, prostate specific antigen, PSM, positive surgical margin, RP, radical prostatectomy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Editor's Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 402 and 403.

 For another article on a related topic see page 317.

PII: S0022-5347(09)00577-1

doi:10.1016/j.juro.2009.02.139

Refers to article:

  • Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer , 18 May 2009

    Ulka N. Vaishampayan, Shanthi Marur, Lance K. Heilbrun, Michael L. Cher, Brenda Dickow, Daryn W. Smith, Samir A. Al Hasan, James Eliason
    The Journal of Urology July 2009 (Vol. 182, Issue 1, Pages 317-323)

The Journal of Urology
Volume 182, Issue 1 , Pages 139-144, July 2009